Jonathan Poole
Vermögen: 43 537 $ am 31.05.2026
Vermögen: 43 537 $ am 31.05.2026
Jonathan Michael Poole is Director at ACADIA Pharmaceuticals, Inc. since 2026.
Mr. Poole is Senior Vice President-Finance at Vertex Pharmaceuticals, Inc. since 2020.
Former roles include Independent Director at Codiak BioSciences, Inc., Senior Vice President at Shire Plc from 2006 to 2014, Chief Financial & Accounting Officer at Genocea Biosciences, Inc. from 2014 to 2018, Investment Manager at Avanti Capital PLC, Investment Manager at Odyssey Partners Ltd. from 2004 to 2007, Head-Strategic Planning & Portfolio Management at Shire Human Genetic Therapies, Inc., and Chief Financial Officer & Treasurer at Evelo Biosciences, Inc. from 2018 to 2020.
Education includes an undergraduate degree from the University of Durham and an MBA from London Business School.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 29.05.2026 | 2.010 ( 0 % ) | 43 537 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 03.03.2026 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01.03.2020 |
| Unternehmen | Position | Ende |
|---|---|---|
| EVELO BIOSCIENCES, INC. | Finanzdirektor/CFO | 27.03.2020 |
| GENOCEA BIOSCIENCES, INC. | Finanzdirektor/CFO | 23.03.2018 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Develops, manufactures and markets pharmaceuticals | Corporate Officer/Principal | 01.03.2014 |
Odyssey Partners Ltd.
Odyssey Partners Ltd. Investment ManagersFinance Provides Investment advisers | Corporate Officer/Principal | 31.01.2007 |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Develops human genetic therapies | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Develops, manufactures and markets pharmaceuticals | Commercial Services |
ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Genocea Biosciences, Inc.
Genocea Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that discovers and develops novel cancer immunotherapies | Health Technology |
Avanti Capital PLC
Avanti Capital PLC Financial ConglomeratesFinance Provides investment management and ancillary services | Finance |
University of Durham
University of Durham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
London Business School
London Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Odyssey Partners Ltd.
Odyssey Partners Ltd. Investment ManagersFinance Provides Investment advisers | Finance |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Develops human genetic therapies | Health Technology |
Evelo Biosciences, Inc.
Evelo Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapeutics for small intestine related diseases | Health Technology |
Codiak BioSciences, Inc.
Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops exosome based therapeutics | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen